News

On 12 Apr 2026, shares plunged by as much as 20 % in early trading after the company warned that 2026 sales and earnings could fall 5 – 13 % and that current‑year revenue could decline up to 13 %. The downtick coincided with a broader sell‑off in the obesity‑drug sector triggered by rivals Eli Lilly’s Mounjaro, which reported a 110 % rise in sales...

Full article

Novo’s shareholder return since 2019 exceeds DKK 300 bn, with a proposed final dividend of DKK 11.70 for 2025. The company’s gross margin fell to 81 % from 84.7 % in 2024 due to amortisation and restructuring costs, and operating profit fell 1 % in DKK. Overall, the company treats nearly 46 m patients worldwide and aims to preserve its leadership i...

Full article

Despite the headwinds, Novo maintains growth in its GLP‑1 pipeline. Early‑stage candidates include CagriSema for type‑2 diabetes and Senagametide (formerly amycretin). The company also advanced an oral GLP‑1RA pill, expected to enter the market in the second half of 2025, with the pill version of Wegovy projected to drive significant weight‑loss (1...

Full article

The guidance triggered a sharp market reaction. Shares fell 18 % in Copenhagen and up to 20 % on 4 Feb 2026 following the 2026 outlook, wiping approximately $32 bn–$47 bn of market value. The decline was driven by expectations of a 13 % drop in 2026 sales and profits, the first negative growth outlook in years, and intensified competition from gene...

Full article

During its Q4 earnings call on 4 Feb 2026, Novo highlighted a forecasted decline of 5 %–13 % in sales and operating profit at constant exchange rates for 2026. The outlook cites lower realized prices, U.S. pricing effects under President Trump’s MFN policy and the IRA, mix and cash‑pay shifts, and the loss of semaglutide exclusivity in Brazil, Cana...

Full article

Novo Nordisk AS reported 10 % sales growth and 6 % operating‑profit growth for 2025 at constant exchange rates. Obesity‑care revenue climbed from DKK 6 bn in 2019 to DKK 82 bn in 2025, a 31 % annual growth rate, while GLP‑1 sales expanded over 30 % in 2025. Wegovy generated DKK 28 bn in international sales, up 134 % versus the prior year, and Ozemp...

Full article

OXB announced a new Commercial Supply Agreement with Bristol Myers Squibb (BMS) to manufacture and supply lentiviral vectors for BMS’ CAR‑T programmes. The partnership, originally established in 2020, will shift to commercial production in 2026, pending regulatory approval. The multi‑year deal is projected to generate significant revenue, reinforci...

Full article

Cars Commerce Inc. (NYSE: CARS) announced a partnership with Del Grande Dealer Group and Salesforce to launch DealerCloud LLC, a new automotive CRM built on Salesforce’s Agentforce Automotive platform. The solution targets long‑standing inefficiencies in auto‑retail CRMs by offering a modern, intuitive system that merges data across OEMs, retailers...

Full article

Wall Street analysts anticipate a year‑over‑year earnings decline for Porch Group, Inc. (PRCH) in the quarter ended December 2025. The consensus EPS estimate is –$0.07 per share, a 146.7 % drop from the same period last year. Revenues are projected at $108.64 million, up 8.3 % from the previous quarter. The Zacks Earnings ESP model signals a negati...

Full article

The appointment comes as Cadiz positions itself to meet rising demand for clean water and energy resources. The company controls 45,000 acres of land in California, 2.5 million acre‑feet of water supply, and 220 miles of pipeline assets. With O’Hara’s guidance, Cadiz aims to address climate‑change‑related challenges to water access and accelerate s...

Full article